Drug Trial News

RSS
Genentech, Biogen report Phase III study data of Rituxan in patients with advanced follicular lymphoma

Genentech, Biogen report Phase III study data of Rituxan in patients with advanced follicular lymphoma

6 Dec 2010
Pivotal Phase II study data of romidepsin in relapsed PTCL presented at ASH 2010

Pivotal Phase II study data of romidepsin in relapsed PTCL presented at ASH 2010

6 Dec 2010
Immunomedics reports results of milatuzumab-based combination treatments for NHL patients

Immunomedics reports results of milatuzumab-based combination treatments for NHL patients

6 Dec 2010
Cyclacel reports preclinical data of CYC065 for treatment of cancer, other serious diseases

Cyclacel reports preclinical data of CYC065 for treatment of cancer, other serious diseases

6 Dec 2010
BioCryst reports Phase 2 trial data of forodesine in patients with CLL

BioCryst reports Phase 2 trial data of forodesine in patients with CLL

6 Dec 2010
Updated Phase 1 study results of FOLOTYN in patients with refractory CTCL presented at ASH 2010

Updated Phase 1 study results of FOLOTYN in patients with refractory CTCL presented at ASH 2010

6 Dec 2010
Alexion Pharmaceuticals reports interim results from phase 1 trial on samalizumab antibody

Alexion Pharmaceuticals reports interim results from phase 1 trial on samalizumab antibody

6 Dec 2010
Positive results from pivotal trial of SGN-35 in refractory Hodgkin lymphoma presented at ASH 2010

Positive results from pivotal trial of SGN-35 in refractory Hodgkin lymphoma presented at ASH 2010

6 Dec 2010
Study: REVLIMID and dexamethasone for high-risk smoldering multiple myeloma reduce risk of disease progression

Study: REVLIMID and dexamethasone for high-risk smoldering multiple myeloma reduce risk of disease progression

6 Dec 2010
Clinical data of PCI-32765 in patients with CLL presented at ASH Annual Meeting

Clinical data of PCI-32765 in patients with CLL presented at ASH Annual Meeting

6 Dec 2010
Lundbeck reports positive phase III study data of clobazam in treating seizures associated with LGS

Lundbeck reports positive phase III study data of clobazam in treating seizures associated with LGS

6 Dec 2010
Positive initial clinical data of IMGN901 used in combination regimen for multiple myeloma presented at ASH Annual Meeting

Positive initial clinical data of IMGN901 used in combination regimen for multiple myeloma presented at ASH Annual Meeting

6 Dec 2010
Phase 2 survival data of sapacitabine in patients with MDS presented at ASH Annual Meeting

Phase 2 survival data of sapacitabine in patients with MDS presented at ASH Annual Meeting

6 Dec 2010
Investigational study data of REVLIMID with rituximab or rituximab-containing regimen in CLL patients presented at ASH

Investigational study data of REVLIMID with rituximab or rituximab-containing regimen in CLL patients presented at ASH

6 Dec 2010
Pivotal PROPEL trial data of FOLOTYN in patients with refractory PTCL reported at ASH Annual Meeting

Pivotal PROPEL trial data of FOLOTYN in patients with refractory PTCL reported at ASH Annual Meeting

6 Dec 2010
QRxPharma completes patient enrolment of pivotal MoxDuo IR phase 3 study

QRxPharma completes patient enrolment of pivotal MoxDuo IR phase 3 study

5 Dec 2010
Clinical studies participated by three investigators to be presented at ASH Annual Meeting and Exposition

Clinical studies participated by three investigators to be presented at ASH Annual Meeting and Exposition

4 Dec 2010
Positive results from Neuraltus NP002 Phase 1/2 study for levodopa-induced dyskinesias in Parkinson's disease

Positive results from Neuraltus NP002 Phase 1/2 study for levodopa-induced dyskinesias in Parkinson's disease

4 Dec 2010
Pharnext receives French approval for Pleodrug Phase II clinical trial in Charcot-Marie Tooth disease type 1A

Pharnext receives French approval for Pleodrug Phase II clinical trial in Charcot-Marie Tooth disease type 1A

4 Dec 2010
Pfizer plans regulatory submissions of bosutinib for CML based on BELA study

Pfizer plans regulatory submissions of bosutinib for CML based on BELA study

4 Dec 2010

Terms

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

Provide Feedback